drugset
drugset / Trial / NCT06375005

Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis

NCT06375005 ↗

Phase 2 Recruiting 38 enrolled Second Affiliated Hospital, School of Medicine, Zhejiang University
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is a prospective, open-label, randomized, controlled, multi-center clinical trial. The aim of this study is to investigate the efficacy and safety of Telitacicept in adults with early diffuse cutaneous systemic sclerosis (dcSSc), with Mycophenolate Mofetil (MMF) administered as a background treatment.

Timeline

Start
2025-01-06
Primary completion
2027-01-06
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Telitacicept Protein / enzyme biologic 160 mg Subcutaneous
Background Mycophenolate Mofetil Small molecule 0.5 g Oral

Indications

diffuse cutaneous systemic sclerosis